%PDF-1.4
%
74 0 obj
<>
endobj
71 0 obj
<>
endobj
152 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-12T10:07:12Z
2024-03-28T11:22:03-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T11:22:03-07:00
application/pdf
Heather
2004-113.dec
uuid:8943dfc6-1dd2-11b2-0a00-6309278d5b00
uuid:8943dfc8-1dd2-11b2-0a00-1e0000000000
endstream
endobj
60 0 obj
<>
endobj
61 0 obj
<>
endobj
75 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 40 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 42 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 44 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 46 0 R/Type/Page>>
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 48 0 R/Type/Page>>
endobj
28 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 50 0 R/Type/Page>>
endobj
31 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 52 0 R/Type/Page>>
endobj
34 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 54 0 R/Type/Page>>
endobj
182 0 obj
[186 0 R]
endobj
183 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6229 0.7822 -0.7822 0.6229 12.739 54.1879 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
12 789 587 -785 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
52.97 77 m
557.97 77 l
S
0 0 0 0 k
493.79 69.86 64.18 -15.66 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
8 0 0 8 540.968 56.9344 Tm
(2373)Tj
ET
0 0 0 0 k
53.03 71 203 -15.66 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.032 58.0696 Tm
[(Kr)36.8 (emers, et al: Therapeutic strategies in RA)]TJ
/T1_2 1 Tf
0.3085 84.8281 Td
[(18.)-875.1 (Pope JE, Hong P)110.7 (, Koehler BE. Prescribing trends in disease )]TJ
2.175 -1.25 Td
(modifying antirheumatic drugs for rheumatoid arthritis: a survey of)Tj
0 -1.25 TD
(practicing Canadian rheumatologists [comment]. J Rheumatol)Tj
0 Tc 0 Tw T*
(2002;29:255-60.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(19.)-875.1 (Galindo-Rodriguez G, )54.8 (A)74 (vina-Zubieta JA, Fitzgerald )54.8 (A, LeClerq SA,)]TJ
2.175 -1.25 Td
[(Russell )54.8 (AS, Suarez-Almazor ME. )17.7 (V)110.8 (ariations and trends in the )]TJ
T*
(prescription of initial second line therapy for patients with )Tj
T*
(rheumatoid arthritis. J Rheumatol 1997;24:633-8.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (Aletaha D, Smolen JS. )17.7 (The rheumatoid arthritis patient in the clin-)]TJ
2.175 -1.25 Td
(ic: comparing more than 1,300 consecutive DMARD courses.)Tj
0 Tc T*
(Rheumatology 2002;41:1367-74.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(21.)-875.1 (Kasman N, Shipton D, Badley EM. Prescribing patterns for )]TJ
2.175 -1.25 Td
(arthritis-related medications over a ten-year period [abstract].)Tj
T*
(Arthritis Rheum 2002;46 Suppl:S122.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Riise )17.7 (T)74 (, Jacobsen BK, Gran JT)73.9 (. Changes in therapy of rheumatoid)]TJ
2.175 -1.25 Td
(arthritis during the period 1979 to 1996. Scand J Rheumatol)Tj
0 Tc 0 Tw T*
(2001;30:199-202.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875.1 (Kurland L, Molgaard C. )17.7 (The patient record in epidemiology)64.8 (. Sci)]TJ
0 Tc 2.175 -1.25 Td
(Am 1981;245:54-63.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(24.)-875.1 (Melton L. History of the Rochester Epidemiology Project. Mayo)]TJ
2.175 -1.25 Td
(Clin Proc 1996;71:266-74.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Doran MF)79.7 (, Pond GR, Crowson CS, O\325Fallon )17.7 (WM, Gabriel SE.)]TJ
2.175 -1.25 Td
[(T)35 (rends in incidence and mortality in rheumatoid arthritis in)]TJ
T*
[(Rochester)39.7 (, Minnesota, over a forty-year period. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2002;46:625-31.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(26.)-875.1 (Gabriel SE, Crowson CS, Maradit Kremers H, et al. Survival in)]TJ
2.175 -1.25 Td
(rheumatoid arthritis: a population-based analysis of trends over 40)Tj
T*
[(years. )54.8 (Arthritis Rheum 2003;48:54-8.)]TJ
-2.175 -1.25 Td
[(27.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-2.175 -1.25 Td
[(28.)-875.1 (Kaplan E, Meier P)110.7 (. Non-parametric estimation from incomplete)]TJ
2.175 -1.25 Td
[(observations. J )54.8 (Am Statist )54.8 (Assoc 1958;53:457-81.)]TJ
-2.175 -1.25 Td
[(29.)-875.1 (Peto R, Peto J. )54.8 (Asymptotically ef)17.7 (ficient rank invariant procedures. )]TJ
0 Tc 2.175 -1.25 Td
(J Roy Stat Soc 1972;135:185-207.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(30.)-875.1 (Cox D. Regression models and life-tables. J Roy Stat Soc)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(1972;34:187-220.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(31.)-875.1 (W)79.9 (einblatt ME, Coblyn JS, Fox DA, et al. Ef)17.7 (ficacy of low-dose)]TJ
2.175 -1.25 Td
(methotrexate in rheumatoid arthritis. New Engl J Med)Tj
0 Tc 0 Tw T*
(1985;312:818-22.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(32.)-875.1 (W)79.9 (einblatt ME, )17.7 (T)35 (rentham DE, Fraser P)91.7 (A, et al. Long-term )]TJ
2.175 -1.25 Td
(prospective trial of low-dose methotrexate in rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1988;31:167-75.)Tj
-2.175 -1.25 Td
[(33.)-875.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Meenan RF)79.7 (. )17.7 (The comparative ef)17.7 (ficacy and)]TJ
2.175 -1.25 Td
(toxicity of second-line drugs in rheumatoid arthritis: results of two)Tj
T*
[(metaanalyses. )54.8 (Arthritis Rheum 1990;33:1449-61.)]TJ
-2.175 -1.25 Td
[(34.)-875.1 (Krishnan E, Fries JF)79.7 (. Reduction in long-term functional disability)]TJ
2.175 -1.25 Td
(in rheumatoid arthritis from 1977 to 1998: a longitudinal study of)Tj
T*
[(3035 patients. )54.8 (Am J Med 2003;1)36.8 (15:371-6.)]TJ
-2.175 -1.25 Td
[(35.)-875.1 (Coste J, Jougla E. Mortality from rheumatoid arthritis in France,)]TJ
2.175 -1.25 Td
(1970-1990. Int J Epidemiol 1994;23:545-52.)Tj
-2.175 -1.25 Td
[(36.)-875.1 (Gabriel SE, Crowson CS, O\325Fallon )17.7 (WM. Mortality in rheumatoid)]TJ
2.175 -1.25 Td
(arthritis: have we made an impact in 4 decades? J Rheumatol)Tj
0 Tc 0 Tw T*
(1999;26:2529-33.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(37.)-875.1 (Kroot EJ, van Leeuwen MA, van Rijswijk MH, et al. No increased)]TJ
2.175 -1.25 Td
(mortality in patients with rheumatoid arthritis: up to 10 years of)Tj
T*
[(follow up from disease onset. )54.8 (Ann Rheum Dis 2000;59:954-8.)]TJ
-2.175 -1.25 Td
[(38.)-875.1 (Lindqvist E, Eberhardt K. Mortality in rheumatoid arthritis patients)]TJ
2.175 -1.25 Td
[(with disease onset in the 1980s. )54.8 (Ann Rheum Dis 1999;58:1)36.8 (1-4.)]TJ
-2.175 -1.25 Td
[(39.)-875.1 (Krause D, Schleusser B, Herborn G, Rau R. Response to)]TJ
2.175 -1.25 Td
(methotrexate treatment is associated with reduced mortality in)Tj
T*
[(patients with severe rheumatoid arthritis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2000;43:14-21.)Tj
-0.00011 Tc 0.02499 Tw 30.825 77.5 Td
[(40.)-875.1 (Choi HK, Hernan MA, Seeger JD, Robins JM, )17.7 (W)79.9 (olfe F)79.7 (.)]TJ
2.175 -1.25 Td
(Methotrexate and mortality in patients with rheumatoid arthritis: a)Tj
T*
[(prospective study)64.9 (. Lancet 2002;359:1)36.8 (173-7.)]TJ
-2.175 -1.25 Td
[(41.)-875.1 (Landewe RB, van den Borne BE, Breedveld FC, Dijkmans BA.)]TJ
2.175 -1.25 Td
[(Methotrexate ef)17.7 (fects in patients with rheumatoid arthritis with )]TJ
T*
(cardiovascular comorbidity [letter]. Lancet 2000;355:1616-7.)Tj
-2.175 -1.25 Td
[(42.)-875.1 (Strom BL. )17.7 (What is pharmacoepidemiology? In: Strom BL, ed.)]TJ
2.175 -1.25 Td
[(Pharmacoepidemiology)64.9 (. )17.7 (W)79.9 (est Sussex, UK: John )17.7 (W)39.9 (iley & Sons)]TJ
0 Tc T*
(Ltd.; 2000.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(43.)-875.1 (Pincus )17.7 (T)74 (, Stein CM. )17.7 (What is the best source of useful data on the)]TJ
2.175 -1.25 Td
(treatment of rheumatoid arthritis: clinical trials, clinical )Tj
T*
(observations, or clinical protocols? [editorial]. J Rheumatol)Tj
0 Tc 0 Tw T*
[(1995;22:161)36.9 (1-7.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(44.)-875.1 (Suarez-Almazor ME. In quest of the holy grail: ef)17.7 (ficacy versus)]TJ
2.175 -1.25 Td
[(ef)17.7 (fectiveness in rheumatoid arthritis [editorial]. J Rheumatol)]TJ
0 Tc 0 Tw T*
[(2002;29:209-1)36.9 (1.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(45.)-875.1 (Choi HK, Hern\207n MA, Seeger JD, Robins JM, )17.7 (W)79.9 (olfe F)79.7 (.)]TJ
2.175 -1.25 Td
(Methotrexate and mortality in patients with rheumatoid arthritis: a)Tj
T*
[(prospective study)64.9 (. Lancet 2002;359:1)36.8 (173-7.)]TJ
-2.175 -1.25 Td
[(46.)-875.1 (Sokka )17.7 (T)74 (, Mottonen )17.7 (T)74 (,)-0.1 ( Hannonen P)110.7 (. Mortality in early \322sawtooth\323)]TJ
2.175 -1.25 Td
(treated rheumatoid arthritis patients during the first 8-14 years.)Tj
T*
(Scand J Rheumatol 1999;28:282-7.)Tj
-2.175 -1.25 Td
[(47.)-875.1 (Bukhari MA, )17.7 (W)39.8 (iles NJ, Lunt M, et al. Influence of )]TJ
2.175 -1.25 Td
(disease-modifying therapy on radiographic outcome in )Tj
T*
[(inflammatory polyarthritis at five years: results from a lar)17.7 (ge )]TJ
T*
[(observational inception study)64.9 (. )54.8 (Arthritis Rheum 2003;48:46-53.)]TJ
-2.175 -1.25 Td
[(48.)-875.1 (W)39.9 (iles NJ, Lunt M, Barrett EM, et al. Reduced disability at five)]TJ
2.175 -1.25 Td
(years with early treatment of inflammatory polyarthritis: results)Tj
T*
[(from a lar)17.7 (ge observational cohort, using propensity models to)]TJ
T*
[(adjust for disease severity)64.8 (. )54.8 (Arthritis Rheum 2001;44:1033-42.)]TJ
-2.175 -1.25 Td
[(49.)-875.1 (Maetzel )54.8 (A, Bombardier C. Give observational studies a chance:)]TJ
2.175 -1.25 Td
(Better observational studies make better economic evaluations. )Tj
T*
(J Rheumatol 1999;26:2298-9.)Tj
-2.175 -1.25 Td
[(50.)-875.1 (Maetzel )54.8 (A, )17.7 (T)35 (ugwell P)110.7 (, Boers M, et al. Economic evaluation of )]TJ
2.175 -1.25 Td
(programs or interventions in the management of rheumatoid )Tj
T*
(arthritis: defining a consensus-based reference case. J Rheumatol)Tj
0 Tc 0 Tw T*
(2003;30:891-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(51.)-875.1 (Gabriel S, Drummond M, Maetzel )54.8 (A, et al. OMERACT)-257.3 (6)]TJ
2.175 -1.25 Td
[(Economics )17.7 (W)79.9 (orking Group report: a proposal for a reference case)]TJ
T*
(for economic evaluation in rheumatoid arthritis. J Rheumatol)Tj
0 Tc 0 Tw T*
(2003;30:886-90.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(52.)-875.1 (W)79.9 (alker )54.8 (AM. Confounding by indication. Epidemiology )]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(1996;7:335-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(53.)-875.1 (Salas M, Hofman )54.8 (A, Stricker BH. Confounding by indication: an)]TJ
2.175 -1.25 Td
[(example of variation in the use of epidemiologic terminology)64.8 (. )54.8 (Am )]TJ
T*
(J Epidemiol 1999;149:981-3.)Tj
-2.175 -1.25 Td
[(54.)-875.1 (Psaty BM, Koepsell )17.7 (TD, Lin D, et al. )54.8 (Assessment and control for)]TJ
2.175 -1.25 Td
[(confounding by indication in observational studies. J )54.7 (Am Geriatr)]TJ
0 Tc T*
(Soc 1999;47:749-54.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(55.)-875.1 (Landewe RB. )17.7 (The benefits of early treatment in rheumatoid )]TJ
2.175 -1.25 Td
(arthritis: confounding by indication, and the issue of timing.)Tj
T*
(Arthritis Rheum 2003;48:1-5.)Tj
-2.175 -1.25 Td
[(56.)-875.1 (W)79.9 (olfe F)79.7 (, Flowers N, Burke )17.7 (T)79.9 (A, )54.8 (Ar)17.7 (guelles LM, Pettitt D. Increase in)]TJ
2.175 -1.25 Td
(lifetime adverse drug reactions, service utilization, and disease)Tj
T*
(severity among patients who will start COX-2 specific inhibitors:)Tj
T*
(quantitative assessment of channeling bias and confounding by)Tj
T*
(indication in 6689 patients with rheumatoid arthritis and)Tj
T*
(osteoarthritis. J Rheumatol 2002;29:1015-22.)Tj
-2.175 -1.25 Td
[(57.)-875.1 (Maradit Kremers H, Nicola P)110.8 (, Crowson C, Ballman K, Gabriel S.)]TJ
2.175 -1.25 Td
(Cardiovascular death in rheumatoid arthritis: a population-based)Tj
T*
[(study)64.9 (. )54.8 (Arthritis Rheum 2004;in press.)]TJ
-2.175 -1.25 Td
[(58.)-875.1 (W)79.9 (olfe F)79.7 (, Mitchell DM, Sibley JT)73.9 (, et al. )17.7 (The mortality of rheumatoid)]TJ
2.175 -1.25 Td
[(arthritis. )54.8 (Arthritis Rheum 1994;37:481-94.)]TJ
ET
0 0 0 0 k
/GS0 gs
101.13 82.08 407.5 -10.83 re
f*
0.5 w
101.13 82.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
112.368 73 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
54 0 obj
<>stream
8;Z\6Bj0jg#itt$j>npX>"Ij.U[8T"rSHb-cqkEQ,kM'6U(\.!hoDqpceSMCKC/R6
r-$_(`5H!mS'>9*q##5?%!(J?-KEea[[>JL6*,=(dLIunm$]V'oB*\2g=1i]9k[k*t1!HL(TK^_*9f[okY?MAdkmF
NZ<2=CA;Wn8@V!4fZ/A6D>!O!mgJNEo\(#joKI.732bg:-V$2R,FG%:\*\(E8Ans/SEluH0XIJ&-CM]01.1HUH
0-Q+W\nu(O6>1ViA.W^.KpCI*+4[oKKL787J9maRh@>2:=9b8'282rjt64kV\]
jU6oW/`TRn7qAC=s)?Wa1Sm_r22V;&Q<\/[/WOFL%?[[P\f:HGG*p:!09!]61&*=FsJf4*a3rXN'4J6@E8>;H%5O)-4\:
\GNtKiiqS("`RRI`mTZ<-_r-SrcTO)H.ThhStpA_%6e]QY?]Q`O>O>UiBo(7?GaUn5oRVaT8J=(c(YcCen;7.KT*MTSfCS%!p+WN@f(p\URDn\U]?GrbdP
>^A!M+?]`!4J2ZF8']ih6;N+L~>
endstream
endobj
58 0 obj
[/Indexed/DeviceRGB 255 57 0 R]
endobj
57 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
135 0 obj
<>
endobj
77 0 obj
<>
endobj
86 0 obj
<>
endobj
118 0 obj
<>
endobj
157 0 obj
<>
endobj
85 0 obj
<>
endobj
111 0 obj
<>stream
H|RiTVB08. 8@1+.
4,
-"pED@3 :*8$b5sr+s;1s3q>~
휵C8ogƳokp,l7R
ɖOB%Xbkq..KԚ$tVscD#u)Z"A+]T'iIr"jT/JZEvS#WR+KuI(E<)NRԺBT*WES'I&VUF)IJWGM HlñOhl!-Ţ1LajbX20,ò0$°ab#0okgf3̮H( -͓+I@pWh'\&~'>jr½NOL2>)u[yNs.ٖ#SVfV
*>+N~,$$SN}Gmjm&촩&V<{m&۶Id3BTvgl[Ǿ`ĹrRTk5Py>RʪZzUw@S%i#)?0PO'pa*ro`T)[xaRHp
ǭM%ri͎B%O덏)ꫲbb`*s Sf{"F.75ߐJ;)NX1eo;lI Njtں< x}"P;Wv&yD!^F?ZٴdJ_SOneE#/$1N6#>s8xK;JU(fd?_;sDuOD>̓yٳ{(ZF,]?rky_ JzڎQ#r03ń708^dFP,vLa^=;A"W-QwH!=y
NCC=
O#Kݩ$̲/GnțF.1H9Jxwo=Uz:\r^XᖢЪKm噧4ﺸlLV.2&6Xמ^tTN[d(ɱ;DW5au՚dݩ-魆+ \]^xUc]odؙɘ^Q\dw97-qɅ5յ"ٛ1cKr{6p&@b]`ժ*5uuUi*97㛌۰6qaגK-)6T[Uc?0)`}
\WtNS)B٦`BpFNhYqvѸiW5>RdX)N:7gꊼiqCr OӦv哫"aR #z%J6ċ0-OU{:ֹ98Bo)6Pe
+$caBkc#ipvٲHEJnd.YtnbwھaE"z_;?$.mu-}OfΌ33w4nj1De!ul;אFȀ1}w
'`9hW
Ȥ (@8ڗA[Nȕ佀
0TuR8id`LG،^BnUp7oX#~~TbT#rA4Za#}&T+R`=o?QW[ BhprEe
Ggu>^G84hۜE̬࿁mCιcզW| >h|U^ DL'o7(d@.@߿&ĆqI~d6A'+TrGlZV2v+}v;SkYgva4Fz0S[$Du
mo5vl]"28(K!T5=ѥjokOijI|}<дoۮ4\q_n]:OW0Bw2ڣ881L
!֊."(E]u@-ʣDp-](OE YpUx\mk{G==w؛zdw}S.OM$FzrH?1kgBGKN%z`L'4+hcx'4cVf=K5AH>T?c>zF\_z
&O :C֑a2c+?x#\S{`5vuHxmlkm*r|R$[#J]9Ժ*isCQEN9cV'IljZԍ()`I|S't̛MVsJDgB&:Zc0ns{?'Jf]nT
<dDam
G;lrF}qnXW~{sګ+bܯW G3
u<}KFQ?+
NUʁv3-yU32"(|ֆ";t!$1 9c'fNWftŷƃ<Z"0MD] *8Bp-GiH t$
lPaOY63g DviuA08?j0\J.L,3*` Mp$(Tb XLw(wg9W/Ŝ2S!*tXAhP=`[_LsaChtR8$0~-z`9/Ѷ@N/I\=Aֿ,J2LpA C00"Вpo;MMB0ڀض8a,nTgnDŽpƨ(%.O6
LUWf@ YHbږ!3
J5z1b'cą,Yr,9E &0cߒ.X,'/f"SU>ceIܾtjSO(
zDpv@7ۨ{NǶMa ٩K< s}aw!Vvww
Lc(&e`ugMGooXP|$ꐊ'I=2d@,[QX8}0E&Q7',YкQ7*hЈ)s4qqq(!.xf
cfd
tw&yGɧrs63ZsRF64QoJ
љL^aay.:r0C4.L<Ρ;)]"q-Ȑᔬw"
JUmW=FɣQH'*)&W+"EwyUrYSQbBvISTF^p$ uL?GǢ]тed0u+`=N%D6cFxm8PU|~L]|Ȁx[b(ZB^T8͛a EUQ$Zy^Mx0E_Q%[I0`(*gL~}TXV9IMFϏKHKIr;fPS%q`q3).0y{NhPRذmٸM-{?Gp~ DA(ŵ;.
Aft%
T=
_+FNZU(
qS8gʴ-*ΔJAiV*p;3h?sHXAxHQYI˕7Uׂ8]tHiRyGEzrG`6&
[.jO"%b/joN>xx3ռ#AWf֨,Lu,3A̵VZFXlZ+/E$GB!@Ix[_bԱmtuqְ^>vZw3*